Ignacio Romero
Overview
Explore the profile of Ignacio Romero including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
82
Citations
1370
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Vasquez D, Giannoni R, Salvatierra A, Cisneros K, Lafosse D, Escobar M, et al.
Int J Gynaecol Obstet
. 2024 Dec;
PMID: 39636171
Objective: To explore the association of maternal characteristics, oxygenation, and mechanical ventilatory parameters with fetal and neonatal outcomes. Methods: The present study was a multicenter, binational (Argentina/Colombia), prospective, cohort study,...
3.
Consensus on drivers of maintenance treatment choice and patterns of care in advanced ovarian cancer
Perez-Fidalgo A, Schmalfeldt B, George A, Gourley C, Pignata S, Lorusso D, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39448084
Objectives: Maintenance therapies, including poly (ADP-ribose) polymerase (PARP) inhibitors and/or bevacizumab, have substantially improved the prognosis of patients with advanced ovarian cancer. Owing to the variability in treatment strategies across...
4.
Hui C, Simiele E, Lozko Y, Romero I, Skinner L, Binkley M, et al.
Front Oncol
. 2024 Oct;
14:1459287.
PMID: 39351359
Introduction: Volumetric modulated arc therapy (VMAT) total body irradiation (TBI) allows for greater organ sparing with improved target coverage compared to 2D-TBI. However, there is limited evidence of whether improved...
5.
Manso L, Ramchandani-Vaswani A, Romero I, Sanchez-Lorenzo L, Bermejo-Perez M, Estevez-Garcia P, et al.
Clin Transl Oncol
. 2024 Aug;
26(11):2771-2782.
PMID: 39215938
Cervical cancer (CC) is the fourth most common cancer and the fourth leading cause of mortality in women worldwide. It is strongly associated with high-risk human papillomavirus infection. High-income countries...
6.
Monk B, Romero I, Graybill W, Churruca C, OMalley D, Knudsen A, et al.
Clin Ther
. 2024 Jul;
46(8):612-621.
PMID: 39019698
Purpose: Niraparib is a poly(adenosine diphosphate [ADP]-ribose) polymerase inhibitor approved for the maintenance treatment of advanced ovarian cancer (OC). Niraparib was originally approved in recurrent OC at a fixed starting...
7.
Rubio M, Manzano A, De Sande L, Estevez-Garcia P, Gordon M, de Prado D, et al.
BMC Cancer
. 2024 Jul;
24(1):803.
PMID: 38970024
Background: Trabectedin in combination with pegylated liposomal doxorubicin (PLD) is approved for the treatment of patients with platinum-sensitive relapsed ovarian cancer. Nevertheless, there is currently limited information regarding this treatment...
8.
Makker V, Perez-Fidalgo J, Valabrega G, Hamilton E, Van Gorp T, Sehouli J, et al.
Gynecol Oncol
. 2024 Jun;
185:202-211.
PMID: 38834399
Objective: To report long-term efficacy and safety of selinexor maintenance therapy in adults with TP53 wild-type (TP53wt) stage IV or recurrent endometrial cancer (EC) who achieved partial remission (PR) or...
9.
Machado I, Claramunt-Alonso R, Lavernia J, Romero I, Barrios M, Safont M, et al.
Int J Mol Sci
. 2024 Apr;
25(7).
PMID: 38612518
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract, with proto-oncogene, receptor tyrosine kinase (), or mutations detected in around 85% of cases. GISTs without...
10.
Romero I, Guerra E, Madariaga A, Manso L
Front Oncol
. 2024 Feb;
13:1304303.
PMID: 38348122
Olaparib, a poly(ADP-ribose) polymerase inhibitor, in combination with the antiangiogenic agent bevacizumab, is approved as maintenance therapy for patients with newly diagnosed stage III or IV epithelial ovarian cancer who...